Eric Haura

Director, Lung Comprehensive Research Center · New York Presbyterian Hospital

Credentials: · · ·

History

Lung Comprehensive Research Center · New York Presbyterian Hospital
Present
Chemical Biology and Molecular Medicine Program · New York Presbyterian Hospital
Present
Moffitt Lung Cancer Center of Excellence · New York Presbyterian Hospital
Present

Fragment-Based Targeting of EMT-Mediated Resistance in EGFR-Mutant Lung Cancer
National Cancer Institute · R21
PI · $433.3K · h. Lee Moffitt Cancer Ctr & Res Inst
2026–2028
Developing CDK12 Inhibitors to Overcome Therapy Resistance in HER2+ and KRAS Driven Breast and Lung Cancers
National Cancer Institute · R01
PI · $3.5M · h. Lee Moffitt Cancer Ctr & Res Inst
2021–2026
Identifying Metabolic Vulnerabilities in Lung Cancer
National Cancer Institute · P01
PI · $10.1M · h. Lee Moffitt Cancer Ctr & Res Inst
2021–2026
Overcoming Resistance to KRAS Inhibitors Through a Fragment-Based Chemoproteomics Approach
National Cancer Institute · R21
Contact PI · $433.3K · h. Lee Moffitt Cancer Ctr & Res Inst
2023–2025

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation
Principal investigator · Terminated · Phase 2
H. Lee Moffitt Cancer Center and Research Institute
2009–2010
Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)
Principal investigator · Completed · Phase 1
H. Lee Moffitt Cancer Center and Research Institute
2007–2010
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
Principal investigator · Terminated
H. Lee Moffitt Cancer Center and Research Institute
2004–2009
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Sub-investigator · Recruiting · Phase 2
H. Lee Moffitt Cancer Center and Research Institute
2025–2030